CTX120 is a B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
| SparkCures ID | 374 |
|---|---|
| Developed By | CRISPR Therapeutics AG |
| Generic Name | CTX120 |
| Treatment Classifications | |
| Treatment Targets |